The exceptional growth of biotherapeutics to a $125 billion industry has brought the benefit of targeted therapy to patients. However, as more and more biotherapeutic "generics" are developed, the risk of unwanted immunogenicity grows. ANP has successfully collaborated with biopharmaceutical companies to create novel solutions for immunogenicity and create new possibilities for biotherapeutics breakthroughs. From our highly sensitive NIDS® Streptavidin & Neutravidin plates to our unrivaled NIDS® immunogenicity assays, ANP is providing the innovation for healthcare transformation.

Lab Work

More Information 

 About Us           Collaborations          Careers           Contact Us

ANP Technologies®, Inc.

824 Interchange Boulevard  Newark, Delaware 19711

302-283-1730 | 302-283-1731 (Alternate Tel)

302-283-1733 (Fax)

  • Black Facebook Icon
  • Black Twitter Icon
  • Black YouTube Icon

Copyright 2020

ANP Technologies®, Inc.